ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm & A...
November 30 2020 - 4:30PM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00am ET on Monday, December 7, 2020 to discuss updated findings
from the first-in-human trial of IMGN632, an antibody-drug
conjugate targeting CD123, in patients with relapsed/refractory
blastic plasmacytoid dendritic cell neoplasm (BPDCN) to be
presented in an oral session at the 62nd American Society of
Hematology (ASH) Annual Meeting on December 5, 2020. During the
call, Dr. Naveen Pemmaraju, Associate Professor in the Department
of Leukemia at MD Anderson Cancer Center, will summarize the data
presented during the oral session and management will provide an
update on the pathway to FDA approval for IMGN632 in BPDCN as well
as recent progress in the acute myeloid leukemia (AML) program.
CONFERENCE CALL INFORMATION
To access the live call by phone, dial (877) 621-5803; the
conference ID is 1795760. The call, along with associated slides,
may also be accessed through the Investors and Media section of
immunogen.com. Following the call, a replay will be available at
the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201130005894/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024